Creating a new generation of small molecule protease inhibitors

Scientific Founders

Lloyd P. Aiello, MD, PhD

Lloyd Aiello

Lloyd Paul Aiello is Professor of Ophthalmology at Harvard Medical School, Director of Joslin’s Beetham Eye Institute and Inaugural Chair of the National Eye Institute Diabetic Retinopathy Clinical Research Network. His research aims to determine the biochemistry and molecular mechanisms underlying early diabetic retinopathy and other retinal vascular disorders, and then develop and test novel therapeutic interventions through translational and clinical trial research. Lloyd has led studies resulting in significant progress toward understanding and manipulating the expression, regulation and signaling functions of vascular endothelial growth factor (VEGF) and its receptors. Lloyd has been a leader in numerous previous and ongoing pivotal trials evaluating the benefit of potent VEGF inhibitors and other treatments for DME.

Dr Aiello is a co-founder of KalVista Pharmaceuticals.

Edward P. Feener, PhD

Ed Feener

Edward P. Feener is an Associate Professor of Medicine at Harvard Medical School and Senior Investigator in the Section on Vascular Cell Biology at Joslin Diabetes Center. His laboratory performs basic and translational research to identify novel mechanisms that activate the plasma kallikrein system and new actions of plasma kallikrein, which contribute to vasogenic edema and the vascular complications of diabetes. Findings from his laboratory have implicated plasma kallikrein as a VEGF-independent mediator of Diabetic Macular Edema. Additional studies from his laboratory have shown that activated plasma kallikrein can also worsen intracerebral hemorrhage and stroke. These findings have shed new light of the roles of the plasma kallikrein system in vascular disorders and diabetic complications. Ed has over 25 years of research experience in vascular biology and diabetic complications, which includes retinal, cerebrovascular, and cardiovascular studies.

Dr Feener is a co-founder of KalVista Pharmaceuticals.